Therefore, IGF-1 may be expected to be a biomarker for hyponatremia-induced sarcopenia and bone loss, although there is limitation that serum IGF-1 level is influenced by IGF-1 derived from organs other than skeletal muscles. The gene discussed is IGF1; the disease is Hyponatremia.